i-Lumen Scientific, Inc. has randomized the first United States patient in its pivotal i-SIGHT2 study, beginning the domestic phase of a multinational trial evaluating whether low-level electrical stimulation delivered through a closed eyelid can improve visual function in people with intermediate-to-advanced dry age-related macular degeneration.
The first U.S. randomization occurred at Texas Retina Associates in Fort Worth. The privately held medical technology company received an Investigational Device Exemption from the U.S. Food and Drug Administration earlier in 2026, allowing the investigational i-Lumen AMD System to be studied at American clinical sites.
The milestone moves i-Lumen Scientific beyond regulatory preparation and into the decisive stage of testing its proposed bioelectric treatment. It does not provide evidence that the system works. No efficacy or safety findings from i-SIGHT2 have been reported, and the device has not been authorized for commercial use in the United States or any other market.
The latest clinical-trial record lists an estimated enrollment of 100 participants, randomized two to one between active microcurrent treatment and a sham procedure. The primary endpoint is the mean change in best-corrected visual acuity at month three, measured using the standardized Early Treatment Diabetic Retinopathy Study letter chart.
That updated design differs from earlier company and study summaries that referred to 120 participants, a month-six primary outcome and longer treatment or follow-up schedules. Protocol amendments are common during multinational device development, but the eventual clinical report will need to explain when and why those changes were made.
Why is the first U.S. randomization important without validating the i-Lumen AMD System?
Beginning U.S. enrollment confirms that i-Lumen Scientific has activated at least one domestic site, trained investigators, supplied investigational devices and implemented a protocol acceptable for study under an FDA Investigational Device Exemption.
These operational achievements matter for a small medical technology company. A pivotal ophthalmic device trial requires standardized refraction, visual-acuity testing, retinal imaging, device calibration, treatment administration, adverse-event monitoring and consistent data collection across several countries.
The U.S. milestone arrived later than the late-April enrollment start previously anticipated by the company. i-Lumen Scientific has not attributed the difference to a particular clinical, manufacturing or regulatory issue, and a revised site-opening schedule does not necessarily indicate a problem with the programme.
The study was already active internationally before the first American patient entered. The updated registry identifies recruiting centres in the United Kingdom, New Zealand and the United States, while the status of individual Australian sites has changed during the study.
Adding U.S. patients should improve geographic diversity and make the dataset more relevant to a future FDA submission. It may also provide experience at retinal practices that could eventually become commercial users if the device is authorized.
None of this reduces the central efficacy risk. i-Lumen Scientific must demonstrate that treated patients experience better visual outcomes than sham-treated patients, not merely that the device can be operated safely across multiple clinics.
How does the revised i-SIGHT2 design test visual acuity against a sham procedure?
The current registry describes i-SIGHT2 as a randomized, parallel-group, sham-controlled and triple-masked clinical device trial. Participants, care providers and outcome assessors are intended to remain unaware of treatment allocation.
Approximately two-thirds of the planned 100 participants would receive active therapy and one-third would receive sham treatment if enrollment follows the two-to-one allocation precisely. This would produce roughly 67 active participants and 33 controls before accounting for withdrawals or missing assessments.
Participants undergo an initial loading regimen followed by seven maintenance treatments over approximately 11 months. Monthly monitoring continues through month 14, which provides about three months of observation after the final scheduled treatment.
The primary outcome is the mean change from baseline in best-corrected visual acuity at month three. A secondary endpoint examines the proportion of treated eyes gaining at least 10 ETDRS letters, equivalent to two lines on the standardized eye chart. Mean visual-acuity change at month six is another secondary measure.
This structure examines both average performance and clinically noticeable improvement. A statistically significant mean difference can sometimes be driven by a small number of strong responders, while a responder analysis indicates how broadly the benefit is distributed.
Masking will be particularly important. Participants may feel active electrical stimulation or perceive differences between an active and inactive procedure. If the sham experience does not convincingly resemble treatment, expectations could influence subjective effort during visual-acuity testing.
Standardized testing reduces this risk but cannot eliminate it. Best-corrected visual acuity can vary with refraction quality, fatigue, lighting, familiarity with the chart and the participant’s willingness to guess letters. Consistency across sites will therefore be almost as important as the headline result.
Which dry AMD patients are represented, and who is excluded from i-SIGHT2?
The study is enrolling adults aged 60 and older with at least one large druse greater than 125 microns and best-corrected visual acuity ranging from 35 to 70 ETDRS letters. That broadly corresponds to vision between 20/200 and 20/40.
The population includes patients with intermediate dry age-related macular degeneration and selected patients with geographic atrophy. However, the trial excludes geographic atrophy involving the centre of the fovea, where irreversible retinal damage may make functional recovery more difficult.
Patients with wet or exudative age-related macular degeneration in the study eye are also excluded. The device is not being tested as a substitute for anti-vascular endothelial growth factor injections used to control abnormal blood-vessel growth in wet AMD.
The protocol excludes people previously treated with intravitreal geographic atrophy medicines such as Syfovre or Izervay. It additionally excludes recent photobiomodulation or short-pulse laser treatment, helping reduce the risk that another intervention could distort the visual-acuity result.
Other exclusions include diabetic retinopathy, certain implanted electrical devices, severe dry eye, uncontrolled diabetes, seizure disorders, chronic migraine and several retinal or ocular conditions capable of affecting vision independently of dry AMD.
These criteria create a cleaner pivotal population but may narrow eventual generalizability. Many older patients with dry AMD have cataracts, glaucoma, diabetes, cardiac devices or overlapping retinal disease. Commercial adoption will ultimately depend on how widely the authorized population resembles patients encountered in routine retinal practice.
Can 100 participants separate a genuine visual benefit from normal ETDRS variability?
A 100-patient trial can identify a meaningful signal if the treatment effect is sufficiently large and consistent. It offers less protection against imbalances, missing data and influential outliers than a programme involving several hundred participants.
The smaller sham group deserves attention. With approximately 33 control participants, a few unexpectedly strong improvements or deteriorations could materially affect the between-group comparison. Baseline visual acuity, disease stage and the number of treated eyes must remain well balanced.
The primary endpoint uses mean letter change, allowing investigators to preserve more information than a simple responder classification. The secondary 10-letter threshold supplies a clinically intuitive measure that is less vulnerable to interpreting a small average change as transformational.
Results should include confidence intervals, not only a probability value. A statistically significant result accompanied by a wide range of plausible treatment effects would leave uncertainty about how much improvement patients can reasonably expect.
Consistency will matter across U.S., British and New Zealand sites. If the apparent benefit is concentrated at one centre, in a small disease subgroup or among participants with a particular baseline acuity, clinicians may question whether the result is reproducible.
The analysis must also account for missing month-three assessments, treatment discontinuations and bilateral disease. The registry specifies use of the treated study eye or a designated primary study eye, which should prevent both eyes from one participant being treated as fully independent observations in the main analysis.
What is the biological rationale for applying microcurrent through a closed eyelid?
The i-Lumen AMD System delivers low-level electrical stimulation through electrodes positioned on the eyelid. The treatment is administered in an office setting and calibrated for the individual participant.
i-Lumen Scientific proposes that the stimulation increases transepithelial potential across the retinal pigment epithelium. This cellular layer supports photoreceptors, transports nutrients and waste products, manages fluid and helps maintain the environment required for visual function.
The company’s hypothesis is that microcurrent can repolarize dysfunctional retinal pigment epithelial cells, improve retinal homeostasis and support photoreceptor signalling. If that process produces a functional effect, patients could read more letters even without regenerating retinal tissue that has already been lost.
The mechanism remains investigational. Delivering an electrical current and observing changes in retinal electrophysiology would demonstrate biological activity, but it would not automatically prove that the treatment alters the clinical course of dry AMD.
Acuity improvement and disease modification are separate claims. The registered primary endpoint tests visual function at month three. It does not, by itself, establish that the device prevents geographic atrophy, slows drusen-related progression or protects vision over several years.
Retinal imaging, electrophysiology and structural biomarkers could provide valuable supportive evidence. The most persuasive programme would connect those biological changes with durable improvements in visual function rather than presenting them as independent signs of activity.
What has i-Lumen disclosed from i-SIGHT, and why is the evidence incomplete?
The pivotal programme follows the 95-participant i-SIGHT feasibility study, which completed follow-up in June 2025. That earlier trial was also randomized, sham-controlled and masked, with device-related serious adverse effects serving as its registered primary safety outcome.
i-Lumen Scientific has reported that treated eyes demonstrated improvements in visual function, retinal electrophysiology and structural markers associated with photoreceptor health. The company has separately indicated that more than half of treated patients achieved an improvement of at least two visual-acuity lines at month three.
Those observations are encouraging, but the publicly available summaries do not provide the complete active-versus-sham analysis. The full denominators, control-group responder rate, confidence intervals, treatment discontinuations and handling of missing observations are necessary to interpret the magnitude of benefit.
The feasibility study’s detailed results have not been posted to the clinical-trial registry. The first-U.S.-patient announcement also did not disclose the complete adverse-event table or numerical findings for retinal structure and electrophysiology.
This does not mean the earlier evidence is negative. It means the public record remains insufficient for independently assessing whether the apparent improvement exceeded sham performance by a clinically persuasive margin.
i-SIGHT2 must supply that comparison prospectively. A larger trial designed around a visual-acuity endpoint should carry more evidentiary weight than selected findings from an earlier safety and feasibility programme.
How does i-Lumen compete with Valeda and injectable geographic atrophy drugs?
The dry AMD market is no longer an entirely treatment-free landscape. Alcon acquired LumiThera and its Valeda Light Delivery System in 2025, giving the ophthalmic device company an FDA-authorized, noninvasive treatment for selected patients with early-to-intermediate dry AMD and non-central geographic atrophy.
Valeda uses photobiomodulation rather than electrical stimulation. Its FDA authorization was supported by a sham-controlled programme in which treatment produced an average visual-acuity improvement of approximately one ETDRS line after about two years compared with untreated controls.
The Valeda indication covers patients with visual acuity between approximately 20/32 and 20/70. i-SIGHT2 permits acuity as poor as 20/200, potentially testing i-Lumen’s system in some patients with more substantial vision loss.
That comparison must remain cautious because the studies use different entry criteria, treatment schedules, endpoints and follow-up periods. i-Lumen Scientific cannot establish competitive superiority through separate trials.
For advanced geographic atrophy, Apellis Pharmaceuticals markets Syfovre and Astellas Pharma markets Izervay. These complement inhibitors are delivered through intravitreal injection and are intended to slow the enlargement of geographic atrophy lesions.
Their pivotal evidence focused on reducing lesion growth rather than restoring lost visual acuity. The i-Lumen programme is pursuing a different proposition by attempting to improve visual function through an injection-free office procedure.
The commercial question is not simply whether electrical stimulation works. i-Lumen must show whether its effect is large enough, sufficiently durable and applicable to enough patients to compete with an authorized noninvasive device backed by Alcon’s commercial infrastructure.
Could an injection-free office procedure overcome a demanding treatment schedule?
Avoiding intraocular injections is an obvious potential advantage. A transpalpebral treatment eliminates needle entry into the eye and could avoid injection-related risks such as endophthalmitis, retinal detachment and intraocular inflammation.
Noninvasive does not mean burden-free. The loading regimen requires repeated office attendance, followed by seven maintenance visits across approximately 11 months. Travel can be difficult for older people with impaired central vision who may no longer drive independently.
Retinal practices must allocate device space, train staff, schedule treatment sessions and establish procedures for calibration, cleaning and maintenance. Reimbursement must compensate for that time without creating excessive cost for patients or payers.
The commercial model has not been disclosed. It is unclear whether i-Lumen Scientific would sell or lease the system, charge for treatment consumables, use a service-based arrangement or seek a strategic commercial partner.
Durability will determine whether the schedule feels reasonable. Patients may accept multiple visits if the therapy produces noticeable and sustained visual improvement. A modest effect that fades before the next treatment would make the logistical burden harder to justify.
The month-14 assessment should therefore be informative even though the primary endpoint occurs at month three. Preserving benefit after the final maintenance treatment would strengthen the case for a manageable long-term regimen.
Which safety, manufacturing and regulatory questions remain before commercialization?
Low-level stimulation is intended to avoid tissue damage, but i-SIGHT2 must document ocular and periorbital adverse events systematically. Investigators will need to monitor discomfort, skin reactions, retinal changes, visual deterioration and conversion to neovascular disease.
The exclusion of patients with pacemakers, defibrillators, certain implants, seizure disorders and chronic migraines suggests that electrical-stimulation precautions may influence eventual labeling. A regulator may require warnings or contraindications even if the pivotal study identifies no serious device-related event.
Manufacturing evidence must show that every system delivers the intended stimulation reliably. Calibration accuracy, electrode placement, software controls, treatment algorithms and electrical-output consistency will all contribute to regulatory review.
An FDA Investigational Device Exemption authorizes clinical investigation. It does not amount to clearance, approval or an endorsement that the device is effective.
i-Lumen Scientific has not publicly defined whether it expects to pursue a premarket approval application, De Novo classification or another regulatory route. Valeda created a Class II category for light-based dry AMD devices, but a microcurrent system uses a different form of energy and may not fit automatically within that classification.
The company will also need an evidence strategy for reimbursement. Payers may ask whether improvement extends beyond an eye-chart score to reading ability, independence, quality of life, reduced progression or lower demand for other retinal care.
What would make i-SIGHT2 persuasive to retinal specialists, regulators and payers?
The primary analysis must show a clear and statistically robust visual-acuity advantage for active treatment over sham at month three. That difference should remain visible at month six and be supported by a meaningfully higher proportion of patients gaining at least 10 letters.
Benefit should appear across study sites and should not depend on a few participants with unusually large gains. Results by baseline acuity, intermediate disease and non-central geographic atrophy will help identify the patients most likely to respond.
The treatment must preserve masking, maintain a low discontinuation rate and show that the apparent benefit survives rigorous handling of missing data. The study report should explain the reduction from the previously announced 120-patient design to the 100-participant registry target and the movement of the primary endpoint from month six to month three.
Safety must remain acceptable during loading, maintenance and post-treatment observation. Structural imaging should show no evidence that short-term acuity improvement is accompanied by accelerated retinal damage or another unfavourable anatomical change.
Longer follow-up must then establish whether repeated microcurrent stimulation preserves vision or changes disease progression. A three-month visual-acuity result could support a regulatory claim, but chronic dry AMD care will require confidence that improvement is reproducible and durable.
Randomizing the first U.S. patient gives i-Lumen Scientific the opportunity to answer these questions in an FDA-supervised pivotal programme. The milestone is significant because dry AMD still leaves many patients with progressive vision loss and few practical interventions.
The next value-changing event will not be another site activation. It will be the first credible active-versus-sham dataset showing whether a carefully controlled electrical current through the eyelid can produce vision patients can use and an effect retinal specialists can trust.
